Companion Animal Protection Against Cruel Testing Act
- Sponsor
- Rep. Langworthy, Nicholas A. [R-NY-23]
- Committees
- Energy and Commerce Committee (primary)
- Last action
- Sep 21, 2026
Bottom line
The bill aims to end the use of live dogs and cats in HHS-funded biomedical research by cutting off federal funding, establishing a framework for accountability, and promoting humane disposition of animals.
What it actually does
This bill prohibits the Department of Health and Human Services (HHS) and its covered agencies from obligating or expending funds for any biomedical research activity involving live dogs or live cats. It broadly defines 'biomedical research' and 'covered activity' while providing specific exclusions for routine veterinary care, animal husbandry, and certain comparative clinical research. The bill also mandates humane disposition for animals previously used in research, establishes a limited waiver for emergencies, and sets forth robust accountability measures including certification, recordkeeping, enforcement, and whistleblower protections.
Proponents argue
Supporters argue that the bill promotes ethical treatment of companion animals, aligning federal spending with public values that increasingly oppose the use of dogs and cats in invasive research. They contend that the legislation will encourage the development and adoption of modern, non-animal research methods that are often more relevant to human biology, ultimately advancing science more effectively and humanely.
Opponents contend
Critics might argue that a blanket prohibition on the use of dogs and cats could hinder critical biomedical research, especially in areas where these species are considered necessary models due to their physiological similarities to humans or the unique nature of certain diseases. They may contend that existing animal welfare regulations are sufficient and that a broad prohibition could delay scientific advancements and the development of new treatments for human conditions.
The bill is relatively short and clearly structured, allowing an informed reader to grasp its core provisions and implications within a reasonable timeframe.
Sec. 3(a), (b)
General Prohibition on HHS Funding for Live Dog/Cat Research
This is the core operative provision, prohibiting any covered Federal agency within HHS (e.g., NIH, CDC, FDA) from obligating or expending funds, directly or indirectly, for any 'covered activity' involving live dogs or live cats. A 'covered activity' is broadly defined to include procurement, breeding, experimental interventions, and even indirect costs, with specific exclusions for non-research animal care or research solely for dog/cat health.
Supporters argue
Supporters argue this direct prohibition is the most effective way to end the use of companion animals in research, ensuring federal taxpayer dollars are not used for practices deemed unethical. They emphasize that the comprehensive definition of 'covered activity' and the anti-circumvention clause are crucial to prevent loopholes.
Critics contend
Critics might argue that such a broad prohibition could severely limit research capabilities, especially if alternative models are not yet fully validated or available for all critical research questions. They may contend that it could delay scientific advancements and the development of new treatments for human diseases.
Tradeoffs
The provision balances ethical concerns for animal welfare with the potential impact on the pace and scope of biomedical research aimed at human health. It seeks to enforce a moral standard while acknowledging the historical role of these animals in certain scientific discoveries.
Sec. 4
Disposition of Live Dogs and Cats
As a condition of receiving HHS funding, recipients must make reasonable efforts to retire, adopt, or transfer live dogs and cats no longer needed for biomedical research to accredited animal sanctuaries, rescue organizations, or adoption programs. Euthanasia is only permitted if a licensed veterinarian determines it's necessary due to the animal's medical, behavioral, or public safety condition.
Sec. 5
Limited Waiver Authority for Emergencies
The Secretary of Health and Human Services may issue or renew a waiver of the Act's requirements only if it is determined, in writing, to be necessary for a public health, national, or national security emergency. The waiver must be limited in duration (180 days, renewable), scope, and only granted if no scientifically valid alternative is reasonably available and failure to grant it would pose a significant and immediate threat. Congress must be notified within 15 days of any waiver.
Sec. 6
Certification Requirements for Funding Recipients
As a condition of receiving HHS funding, recipients must certify, both before receiving funds and annually thereafter, that they will not use the funding for any covered activity, have implemented internal controls for compliance, and that all representations are true and accurate. Recipients must notify the Secretary within 30 days of discovering noncompliance, with potential funding withholding for violations.
Sec. 7
Recordkeeping, Audits, and Access to Records
Recipients of HHS funding must maintain records for at least 6 years to demonstrate compliance with the Act, including procurement, animal acquisition, financial records, and internal audit reports. They must also provide reasonable access to facilities, personnel, and records to the Secretary, the HHS Inspector General, and the Comptroller General for oversight purposes, subject to protections for classified or confidential information.
Sec. 10
Whistleblower Protections
The bill prohibits retaliation against employees, contractors, students, or other individuals who, in good faith, report suspected violations of the Act, provide information to authorities, participate in investigations, or refuse to engage in prohibited conduct. The Secretary must establish procedures for investigating complaints and can require corrective actions for substantiated violations.
Sec. 11
Transparency and Annual Reporting
The Secretary of HHS must submit an annual report to Congress (House Energy & Commerce, Senate HELP committees) on the implementation of the Act. This report must include details on funding applications reviewed, certifications received, awards withheld, audits conducted, the status of rehomed animals, recovered funds, corrective actions, guidance issued, and recommendations. The report must also be made publicly available online.
Sec. 14
Effective Date
The Act's provisions will apply only to federal funding obligated or expended on or after the date that is 180 days after the date of its enactment. This provides a transition period for agencies and recipients to adjust to the new requirements.
Prohibits recipients from circumventing the funding ban by using non-Federal funds for animal acquisition while charging other research costs to Federal funds, transferring activities to affiliated institutions, conducting activities through subcontractors, or dividing a project into multiple funding sources to conceal the use of Federal funds.
Sec. 3(c)
Why it matters:This is standard legislative practice to prevent evasion of the primary intent of the law. Its detailed nature makes it a critical enforcement tool that could be missed by a casual reader focusing only on the general prohibition.
Case for: Supporters argue this clause is essential to prevent institutions from exploiting loopholes and ensure the spirit of the law is upheld, preventing federal funds from indirectly supporting prohibited research. It ensures the ban is comprehensive and effective.
Case against: Critics might argue that it could be overly broad or difficult to enforce without inadvertently penalizing legitimate, separately funded research. It could also create complex accounting challenges for institutions with mixed funding sources, increasing administrative burden.
Estimated impact: Potentially significant, as it closes off avenues for institutions to continue dog/cat research with mixed funding, ensuring the ban is comprehensive and preventing indirect federal support for such activities.
Excludes several activities from the definition of 'biomedical research,' including routine veterinary diagnosis/treatment, ordinary animal husbandry, noninterventional observation, research conducted solely for the health or physiology of dogs or cats, and comparative clinical research involving client-owned dogs or cats with naturally occurring disease (e.g., NCI's Canine Cancer Immunotherapy Network).
Sec. 2(1)(C)
Why it matters:This is standard practice for defining the precise scope of a law and preventing unintended consequences. The specific carve-outs are substantively important as they clarify what the bill does *not* prohibit.
Case for: Supporters argue these exclusions are vital to ensure the bill does not inadvertently harm animal welfare (by prohibiting veterinary care) or stifle valuable comparative medicine research that directly benefits companion animals and has potential human relevance without invasive experimental use of animals.
Case against: Some extreme animal rights advocates might argue that any use of animals in research, even comparative clinical studies, should be prohibited. However, these specific exclusions are generally seen as reasonable compromises that prevent overreach.
Estimated impact: Ensures that the bill's focus remains on experimental biomedical research, rather than impacting routine animal care or specific types of observational/clinical research that are widely supported and beneficial to animal health.